Company Overview and News
Medtronic (MDT - Free Report) has taken its existing relationship with Mazor Robotics to the next level. In a bid to grow further in the field of robotics spine surgery, Medtronic decided to acquire the Israel-based robotic surgical guidance systems company for $1.64 billion in cash.
MASI AMED ISRG UTX MZOR MDT EOG
On Sep 18, we issued an updated research report on Insulet Corporation (PODD - Free Report) . We are upbeat about the company's series of developments with respect to expansion of Omnipod's market reach while a tough competitive landscape raises concerns. The stock carries a Zacks Rank #3 (Hold).
MASI AMED ISRG PODD
With a market capitalization of approximately $30.39 billion, Align Technology’s (ALGN - Free Report) solid Invisalign Technology prospects and growth in North America and outside should continue to boost top-line results. The strong uptake of iTero scanners across all geographies is encouraging as well.
MASI ALGN AMED ISRG
Chicago, IL – September 19, 2018 - Stocks in this week’s article include: Insperity (NSP - Free Report) , Amedisys (AMED - Free Report) , Comfort Systems (FIX - Free Report) , Genesco (GEN - Free Report) and Forward Air (FWRD - Free Report) .
RYAM ESE AMED FWRD ON CVTI UNFI GTS NSP INT TSC
ResMed (RMD - Free Report) recently expanded its AirFit mask portfolio with the introduction of its first minimal-contact full face CPAP mask — AirFit F30. The company plans to launch the product in selected geographies in late-2018.
MASI RMD AMED RMD ISRG
Of late, QIAGEN N.V. (QGEN - Free Report) announced its new development under the company’s long-standing partnership with In Vitro Diagnostics (IVD) player DiaSorin. This time, the companies’ alliance is set to offer a fully-automated CE-Marked testing for latent tuberculosis (TB) infection with QuantiFERON-TB Gold Plus Blood Collection Tubes (QFT-Plus BCT) on DiaSorin LIAISON Platforms.
MASI TXN MDPEB AMED ISRG MDP
Abbott (ABT - Free Report) has been gaining investors’ confidence on consistently positive results. Over the past year, the company’s stock has outperformed its industry. The stock has gained 29.9%, compared with the industry’s 19.8% and the S&P 500’s 16.6%.
MASI MDPEB AMED ISRG MDP
QIAGEN N.V. (QGEN - Free Report) recently collaborated with NeuMoDx Molecular, Inc. to market two new fully integrated systems for automation of PCR (polymerase chain reaction) testing. Furthermore, the companies are partnering to apply certain QIAGEN chemistries on the NeuMoDx systems.
MASI AMED ISRG
On Sep 14, we issued an updated research report on Omnicell, Inc. (OMCL - Free Report) . We are upbeat about gains from the company’s recent buyouts, while increasing operating expenses are denting the bottom line. The stock carries a Zacks Rank #3 (Hold).
MASI OMCL AMED ISRG
On Sep 12, we issued an updated research report on Cardiovascular Systems, Inc. (CSII - Free Report) . Tough competition, consistent operating loss and an anticipated failure to grow business overseas continue to pose threats to this stock. The player carries a Zacks Rank #5 (Strong Sell).
MASI ABT CY CSII AMED ISRG ABT
Penumbra Inc. (PEN - Free Report) has been gaining investor confidence on consistently positive results. In the past year, the company’s share price has outperformed its industry. The stock has soared 74.8% comapred with the industry’s 7.5% rise.
MASI AMED PEN ISRG
With a market capitalization of approximately $20.99 billion, IDEXX Laboratories, Inc. (IDXX - Free Report) is a leading developer, manufacturer and distributer of products and services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. We are specifically upbeat about the company's organic revenue growth trend. Its Companion Animal Group (CAG) business also remains strong on global Catalyst One uptake.
MASI IDXX AMED ISRG
With a market capitalization of approximately $8.70 billion, QIAGEN N.V. (QGEN - Free Report) offers one of the broadest portfolios of molecular technologies for human healthcare. We are specifically upbeat about QuantiFERON-TB test maintaining a dynamic double-digit growth pace and the company being on track with its target for $300 million of annual sales by 2020.
MASI AMED ISRG
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to AMED / Amedisys, Inc. on message board site Silicon Investor.
as of ET